MBB Public Markets I LLC Makes New Investment in Pfizer Inc. $PFE

MBB Public Markets I LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, HoldingsChannel reports. The firm bought 12,098 shares of the biopharmaceutical company’s stock, valued at approximately $307,000.

A number of other large investors also recently bought and sold shares of the company. Ascent Group LLC lifted its holdings in Pfizer by 47.0% during the 1st quarter. Ascent Group LLC now owns 102,350 shares of the biopharmaceutical company’s stock worth $2,594,000 after buying an additional 32,713 shares during the last quarter. Arete Wealth Advisors LLC lifted its holdings in Pfizer by 17.7% during the 1st quarter. Arete Wealth Advisors LLC now owns 102,164 shares of the biopharmaceutical company’s stock worth $2,589,000 after buying an additional 15,392 shares during the last quarter. Great Lakes Advisors LLC lifted its holdings in Pfizer by 381.0% during the 1st quarter. Great Lakes Advisors LLC now owns 80,383 shares of the biopharmaceutical company’s stock worth $2,037,000 after buying an additional 63,670 shares during the last quarter. Bell Investment Advisors Inc lifted its holdings in Pfizer by 21.6% during the 1st quarter. Bell Investment Advisors Inc now owns 3,828 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 681 shares during the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $3,185,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. HSBC dropped their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Finally, Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Down 0.5%

PFE opened at $24.59 on Thursday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market cap of $139.79 billion, a P/E ratio of 13.08, a P/E/G ratio of 0.88 and a beta of 0.55. The stock’s 50 day moving average price is $24.83 and its 200 day moving average price is $24.33.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the firm earned $0.60 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.